Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Mazdutide at 16 mg was well tolerated and associated with greater weight loss at higher doses than previously studied and improved metabolic regulation in adults with overweight or obesity. US Clinical Trials Registry: NCT05623839.
Authors
- Melissa K. Thomas (ORCID: https://orcid.org/0000-0001-9848-2834)
- Lai Tham (ORCID: https://orcid.org/0000-0002-1249-8526)
- Yuanyuan Tang (ORCID: https://orcid.org/0000-0001-6873-9467)
- Sirel Gurbuz
- Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
- Wei Ni (ORCID: https://orcid.org/0000-0003-3494-9217)
- Li Yan (ORCID: https://orcid.org/0000-0002-2218-8644)
- Shobha Bhattachar
- Laiyi Chua
- S. Ng
- Hilda Ibriga
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1111/dom.70040
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Eli Lilly and Company